Daldrup-Link Heike E
1 Department of Radiology, Molecular Imaging Program at Stanford, Stanford University, Stanford, CA, USA.
2 Department of Pediatrics, Lucile Packard Children's Hospital, Stanford University, Stanford, CA, USA.
Mol Imaging. 2017 Jan-Dec;16:1536012117730950. doi: 10.1177/1536012117730950.
This invited commentary discusses a recent article by Mohanty et al in Molecular Cancer Therapeutics about significant therapeutic efficacies of novel theranostic nanoparticles (TNPs) for the treatment of human brain cancers in mouse models. The TNPs were cleaved by enzymes in the tumor tissue, matrix metalloproteinase (MMP-14), which lead to release of a highly potent therapeutic drug, azademethylcolchicine. Data showed that the TNPs caused selective toxic effects in MMP-14-expressing glioblastoma and not normal brain. In addition, the iron oxide nanoparticle backbone enabled in vivo drug tracking with magnetic resonance imaging (MRI). This commentary discusses previous efforts of MMP-targeted therapeutics as well as opportunities for further refinements of tumor enzyme-activatable TNPs. If successfully translated to clinical applications, the TNPs might hold substantial potential to improving cytotoxic indexes and long-term outcomes of patients with brain cancer compared to standard therapy.
这篇特邀评论讨论了莫汉蒂等人发表在《分子癌症治疗学》上的一篇近期文章，该文章介绍了新型治疗诊断纳米颗粒（TNP）在小鼠模型中治疗人类脑癌的显著治疗效果。TNP在肿瘤组织中的基质金属蛋白酶（MMP - 14）作用下被裂解，从而释放出一种高效治疗药物氮杂去甲基秋水仙碱。数据表明，TNP对表达MMP - 14的胶质母细胞瘤具有选择性毒性作用，而对正常脑组织无此作用。此外，氧化铁纳米颗粒骨架能够通过磁共振成像（MRI）进行体内药物追踪。本评论讨论了以往针对MMP的治疗方法，以及进一步优化肿瘤酶激活TNP的机会。如果成功转化为临床应用，与标准治疗相比，TNP可能在提高脑癌患者的细胞毒性指数和长期治疗效果方面具有巨大潜力。
